GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic PDAC

The goal of this clinical trial is to evaluate the safety and efficacy of GnP combined with SHR-1701 and Apatinib as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma.

Trial Details

NCT ID
NCT07802184
Phase
PHASE1 / PHASE2
Sponsor
West China Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • SHR-1701
  • Apatinib
  • gemcitabine
  • Nab-paclitaxel
Locations (sample)
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • 1\) Age 18-75 years, regardless of sex; 2) patients with histologically confirmed pancreatic ductal adenocarcinoma (PDAC); 3) previously untreated …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →